Skip to main content
OpenTrials
Completed

NCT Number: NCT07211295

Accurate AI-based Characterisation of Surface Size, Depth and Tissue Composition in Hard-to-Heal Wounds

This study aims to determine and evaluate the clinical accuracy, precision, and safety of SeeWound 2, an AI-driven wound assessment application, designed for the measurement of wound surface area (cm²), wound depth (mm), and the estimation of the proportion of fibrin covering (slough) and necrosis (%) in real-world clinical settings for patients with hard-to-heal wounds. The study also seeks to validate the non-invasive method for measuring wound depth, as current standard care involves invasive probing of the wound to estimate depth - a practice that this investigational device is intended to replace with a digital, contact-free measurement approach.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

BRIVA, Intensive Care for Burns,

Linköping, Östergötland County, 58185, Sweden

About this study

SeeWound 2 is a software-based medical device that utilises artificial intelligence to classify and quantify wound tissue types, specifically fibrin covering (slough) and necrosis, as well as to measure wound surface area and depth through digital image analysis. The system operates as a mobile camera-based application, whereby healthcare professionals capture an image of a hard-to-heal wound. The software then automatically analyses the image using integrated AI models in combination with the LiDAR sensor technology embedded in the mobile camera hardware. The product's capability to automatically measure wound surface area, estimate wound depth in a non-invasive manner, and objectively quantify the proportion of slough and necrosis within the wound bed represents a novel functionality not currently available in clinical practice.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Older than 18 years, men and women Difficult to heal wounds due to diabetes, VLU; Pressure wounds wound larger than 0.5 cm2

Exclusion criteria

Exclusion criteria

/ Contraindications

Use of SeeWound 2 is not intended for, or is contraindicated in, the following situations:

Patients under 18 years of age. Wounds located in anatomical regions where the full wound surface and depth cannot be captured (e.g. deep fistulas, tunnels, or undermined areas not accessible through surface imaging).

Wounds with excessive exudation or infection that prevents adequate visual assessment.

Patients who are unable or unwilling to provide informed consent. Patients with a known allergy or adverse reaction to any component used in the image acquisition process (where applicable).

Wounds with specific identifiable attributes (e.g. on the face, or containing birthmarks or tattoos) where ethical considerations regarding data handling apply.

Treatment and study plan

Primary outcomes

  1. Accuracy

    Time frame: During the study

    Regular outcome measures for a Medical Device

  2. Accurac, Precision, Mean absolute Error (MAE); Coefficient of Variation (CV); SD

    Time frame: During the study

    Regular outcome measures for a Medical Device

Sponsors and collaborators

Lead sponsor

University Hospital, Linkoeping

Other

Registry information

Official study title

Accurate AI-based Characterisation of Surface Size, Depth and Tissue Composition in Hard-to-Hea Woundsl

Acronym: SeeWound2

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Oct 7, 2025
Registry last updated
Oct 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.